WuXi PharmaTech Corporate Venture, part of the eponymous China-based drugs maker, has participated in a $30 series A round of funding into US-based biotech start-up Syros Pharmaceuticals. Syros has also picked Nancy Simonian, formally of Millennium Pharmaceuticals, as chief executive.
Venture capital firms Flagship Ventures and Arch Venture Partners led the round with participation from undisclosed private investors.
The new funds will be used to accelerate the growth of its gene control regulators called super enhancers.
Syros Pharmaceuticals was co-founded by Arch Venture Partners and Flagship’s VentureLabs unit.